Investment Opportunity

The Pharma Company Looking to Conquer Heart Failure!


Cardiol Therapeutics | Listed on: NASDAQ:CRDL | TSX:CRDL.TO

Get the full report now

Who is Cardiol Therapeutics?


Cardiol Therapeutics is a clinical-stage life sciences company based in Ontario, Canada. The company is focused on researching and developing cannabidiol as an anti-fibrotic and anti-inflammatory therapy to treat cardiovascular disease (CVD).

David Elsley, one of Cardiol’s founders and President and CEO, has had an active interest in inflammation's role in cardiovascular disease for many years. Mr. Elsley has a keen interest in heart failure, which occurs when the heart can no longer pump blood sufficiently for the body’s needs.

In fact, Cardiol is the second company founded by David Elsley in this field. The first was Vasogen Inc., a biotechnology company focused on treating systolic heart failure.

Mr. Elsley turned Vasogen into a NASDAQ-listed $1bn company. While there, he helped advance two anti-inflammatory therapies from concept right through to the completion of international multi-center pivotal Phase III clinical trials involving 2,500 patients.

Mr. Elsley has brought several team members from his predecessor company to Cardiol Therapeutics, and their collective expertise goes a long way in driving the success of Cardiol.

Cardiol’s lead product candidate, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation, which is being clinically developed for cardiovascular medicine use.

The pre-clinical data for this is very compelling, as it shows cannabidiol has potent anti-fibrotic and anti-inflammatory properties. It's this data that has led so many esteemed individuals to back these trials and invest themselves in the Cardiol Therapeutics journey.


Why You Should Consider Investing

  • Treating Diastolic Heart Failure

    Their subcutaneous cannabidiol formulation is an ideal drug candidate for the potential treatment of diastolic heart failure.

  • Acute Myocarditis Cases are Rising

    Under 35s are increasingly susceptible to acute myocarditis, particularly athletes. This is raising alarms and driving interest in workable treatments.

  • Orphan Drug Designation

    Benefits from orphan drug designation include marketing exclusivity rights, high reimbursement levels and regulatory fast-tracking.

  • Independent Board

    Board members are highly qualified, independent, and interested in seeing Cardiol succeed.

  • Scientific and Medical Community Backing

    Cardiol’s leadership and advisory teams include some of the biggest names in cardiovascular medicine.

  • Stable Financial Position

    Cardiol Therapeutics is fully funded into 2024 and has no debt.

Company Information

Cardiol Therapeutics Stock Information:

Exchange / Symbol
Market Capitalization
$ (usd)
Current price
$ (usd)
Current mid price
$ (usd)
52 Week high price
$ (usd)
52 Week low price
$ (usd)

About the Healthcare Sector


There are 64.3 million people with heart failure globally, and it remains a leading cause of death and hospitalization. Associated annual healthcare costs in the U.S. alone exceed $30bn.

While lifestyle changes can reduce the likelihood of heart failure, this is not as easy as it sounds, and every year over 550k new cases are diagnosed in the U.S. That’s why Cardiol Therapeutics is working vigorously to develop therapeutic treatments - to help people live more comfortably with this destructive disease.

This is a massive health problem in the western world that has no current standard of care and is a condition that continues to grow due to increases in diabetes, hypertension and obesity. And, if Cardiol Therapeutics achieves its long-term goal of developing a cannabidiol-based treatment for diastolic heart failure, the resultant addressable market is huge.

Treating Acute Myocarditis and Diastolic Heart Failure

Today, Cardiol Therapeutics’ focus is on treating inflammatory heart conditions, particularly acute myocarditis and diastolic heart failure.

Cardiol Therapeutics wants to prove that its flagship drug, CardiolRx™, is a safe and effective treatment for these life-threatening problems, neither of which currently have an approved standard of care.

Consequently, the market potential for treatment in this area is massive.


Financial Overview and Investor Outlook

Cardiol Therapeutics is very well funded right through to 2024 and has no debt. As of 31 March 2022, it has $74.8m in the bank and 11% of its shares were insider and employee-owned. It also had 4% ownership by pharmaceutical partners and research collaborators.

Helping to advise Cardiol are some of the world’s leading experts in cardiovascular medicine. The company also boasts a variety of esteemed individuals on its Board of Directors, as well as an outstanding group of doctors on steering committees, all rooting for Cardiol’s success

Many pre-eminent medical leaders want to see Cardiol’s trials succeed because, to date, there’s never been a satisfactory treatment for diastolic heart failure. If the Company’s cannabidiol-based drug proves to be that elusive treatment, it will surely be a cause for celebration.

Cardiol’s Trials

There’s great excitement for the efficacy of CardiolRx™ in multiple use cases and, therefore, the potential for the company to profit from several revenue streams.

Cardiol Therapeutics’ involvement in clinical trials currently focuses on CardiolRx™ for two potential treatments.

Acute Myocarditis Trial

Cardiol expects to soon begin a multi-national Phase II trial designed to evaluate the efficacy and safety of CardiolRx™ in acute myocarditis. This condition remains a significant cause of acute and fulminant heart failure in young adults and is a leading cause of sudden cardiac death in people under 35 years old.

COVID-19 Patient LANCER Trial

CardiolRx™ is also being investigated in a Phase II/III LANCER study - the company's most advanced trial. This trial is designed to evaluate the efficacy and safety of CardiolRx™ as a cardioprotective therapy to reduce major cardiovascular and respiratory events in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, CVD. It will also investigate the influence CardiolRx™ has on key biomarkers associated with heart disease.

Development of Diastolic Heart Failure Therapy

Additionally, Cardiol is advancing its development of a subcutaneous cannabidiol formulation as a potential anti-fibrotic and anti-inflammatory therapy for treating inflammation in the heart that is associated with the development and progression of heart failure.

Leadership Team

Cardiol’s comprehensive team has all the bases covered. It includes exceptional management, an impressive and independent Board of Directors, and renowned Scientific and Business Advisors.

  • David Elsley, MBA

    President and CEO

    In 1990, Mr. Elsley founded Vasogen Inc., a biotech company developing novel therapeutics to treat heart failure and other inflammatory conditions. Mr. Elsley managed Vasogen’s growth and established the R&D infrastructure, partnerships, manufacturing capability, and corporate quality systems necessary to advance two anti-inflammatory therapies to pivotal Phase III clinical trials involving 2,500 patients.

  • Dr. Guillermo Torre-Aminone, MD, PhD


    Dr. Torre-Amione serves as Cardiol’s Chair of the Board. He is an esteemed gentleman with highly impressive credentials and experience. Board-certified in cardiovascular disease and Advanced Heart Failure/Transplant Cardiology, Dr. Guillermo Torre-Amione is Professor of Cardiology at The Methodist Hospital Research Institute, Houston, Professor of Medicine at the Weill Cornell Medical College of Cornell University, New York, and President of TecSalud, an academic medical center and medical school in Mexico.

  • Jennifer M. Chao, BA


    The most recently appointed Board member and Wall Street veteran, Ms. Chao, has over 25 years of experience in the biotech and life sciences, focusing primarily on finance and corporate strategy.

  • Colin G. Stott, BSc (Hons)


    Mr. Stott is a world-leading pharmacologist in cannabidiol treatments. He is a former Director for GW Pharma and veteran of the pharmaceutical and biotech industries, having almost 30 years of experience in pre-clinical and clinical development.

Investment Summary: Where's the Value?

This business has massive upside potential if its trials prove what so many leading experts suspect could be true.

Cardiol Therapeutics has assembled some of the biggest names in cardiovascular medicine on its management team, board of directors, scientific advisory board and steering committees for the company’s clinical trials.

Their involvement is a powerful endorsement of Cardiol, while also providing invaluable knowledge and expertise to guide the company through its clinical trials.

Ultimately, with heart failure being one of the western world’s leading causes of death, there’s plenty of interest in seeing Cardiol’s investigations triumph.

Cardiol presents investors with an early investing opportunity. This is a chance to own a piece of a little-known company operating in a ground-breaking area of science.

If Cardiol Therapeutics achieves its long-term goal of developing a cannabidiol-based treatment for diastolic heart failure, the addressable market is immense.

Check out our full analyst report, now!

Learn all about this exciting investment opportunity! Access Cardiol Therapeutics’ in-depth Report for FREE.



This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of One Hundred and Eighty Thousand Dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.